SU1680200A1 - Method for curing the cases of acute virus hepatitis - Google Patents

Abstract

The invention relates to medicine, namely to infectious diseases. The purpose is to reduce the duration of treatment by increasing antiviral activity in patients with HBsAg + moderately severe hepatitis. To do this, reaferon is administered in a dose of 1x10 ME twice a day intramuscularly for 7-10 days, which allows halving the duration of HBSA - antigenemia and jaundice, reducing the frequency of viral superinfections, and preventing chronization of the process.

Description

The invention relates to medicine, namely to infectious diseases.

The purpose of the invention is to reduce the treatment time by increasing antiviral activity in patients with HBsAg + moderate hepatitis.

The method is carried out as follows.

1 x 106 IU of reaferon a is dissolved in 1 ml of physiological saline and administered intramuscularly with an interval of 12 hours for 7-10 days.

PRI me R 1. Ill R., 22 years old. He was admitted with a diagnosis of viral hepatitis B. The pre-icteric period was of a mixed variant, lasting for 6 days. History of blood taken from a finger in April

1987 On admission the state of average heavy metal. Complaints of severe weakness, nausea, pain in zpigastrii. Ill in la, sleepy. Jaundice of medium intensity. In the lungs, vesicular respiration. Pulse 72 beats / min. Muffled heart sounds. A / D 100/65 mmHg The tongue is coated with white bloom. The liver is 2 cm below the costal arch, painful, spleen at the costal arch. The urine is dark, the stool is acholic. From 23.06: total bilirubin 216 μmol / l; ALT 2660 nmol / SL; sublimate titer 1.7 ml; prothrombin index 70%; Er 4.3 x 1012 / l; L 4.4 x 109, ESR 10 mm / h; serum excretion of HBsAg.

Taking into account intoxication syndrome (weakness, drowsiness, nausea, anorexis), inO

oo o u o o o

The intensity of jaundice, an increase and tenderness of the liver, biochemical analyzes - hyperbiruyrnemnemi up to 216 μmol / l; ALT - 2660 nmol / SL; sublimate titer 1.7 ml; the manifestation of HBsAg, - clinical diagnosis of viral patitis B, HBsAg (+), and middle grade was made.

General therapy was prescribed: diet, bed rest, detoxification therapy (5% glucose, quartosol, hemodez up to 2 liters per day, cocarbo intravenous strength, 5% ascorbic acid solution). From the 3rd day of hospitalization, intramuscular administration of IFN-alfaafa, 1 x 106 IU, 2 times a day for 10 days was started.

On the 4th day of the use of the drug (7th day of jaundice), the patient's condition improved: vils appetite, sleep was restored, and past pain was in an instance. By day 12 of jaundice, total bilirubin was reduced to 45 µmol / l, ALT was 348 nmol / cl, and no HBsAg was detected in the blood by the RPHA method. In the future, the patient was carried out only basic therapy. The course of the disease was favorable. By the 14th day of jaundice, the size of the liver was normalized, by the 24th day the activity of enzymes decreased to the norm, the total bilirubin was 35 μmol / l. The patient was discharged in a satisfactory condition. Bed day was 24 days. For 8 months after discharge of exacerbations, there was no relapse.

G p v m e r 2. Patient K, 33 years. Cho 2 CI6 of 18.05.87 was admitted with a diagnosis of viral hepatitis 3, with complaints of weakness, anorek, nausea, vomiting, pain in the stomach, dry mouth Bo / iasJ from 1.05. The pre-tush period of protylt on e-18sha N9mu uvvaviy (dyspepsch-es:; and l gsteno-eereiatmvn u) was 0 days. Lrie poscuvdei / si sogectinome cousin Ј: cheg;, lg, /.in a / in, in the department of omor pyotrans psora; Heart sounds are muffled. Languages: dry, lined. The liver is 8 cm below the rib dun, of a dense consistency, the spleen is not palpable. Aholmchny chair. Taking into account smids of injections (vlost, adinami, vomiting, aiorexi), the presence of jaundice, hepatomegaly, and biohiglic analyzes (from 19.05) - bilmrubin total 241 MCRLOL / L; ALT 862 nmol / SL; sublimate titer 1.7 ml; prothrombin index 64%; the manifestation of HBsAg in the blood, a clinical diagnosis was made of viral hepatitis B, HBsAg (+), and mild severity.

Treatment prescribed: diet, bed

regimen, detoxification therapy (5% for glucose, kvastasol, gemodez, 5% for ascorbic acid, cocarboxylase). From 3 days of hospitalization started, taking into account severe intoxication, intravenous drip administration of IFN-alpha-1x10 eme 2 times a day for 3 days, then continued intramuscularly for 7 days. . The general course of interferon therapy was

10 days. On day 3 of his administration (jaundice day 7), the patient's condition improved; weakness diminished, headaches subsided, appetite suppressed. By the end of the course of IFN-alpha2, total blood bilirubin was 78 µmol / L (decreased 2.5 times); ALT 845 nmol / SL; HBsAg in the blood you did not vils (by day 14 of jaundice). The condition became satisfactory by the 10th day of jaundice, the stool was colored by the 8th day of jaundice. The patient was in the hospital for 33 days. Discharged in satisfactory condition without residual effects. Follow-up observation for 6 months of exacerbations, relapse did not reveal.

The method is applied in 85 patients with acute

viral hepatitis in HBsAg + moderately heavy. The use of the proposed method of treatment resulted in a reduction in the duration of HB8-antigenemia from 19.0 ± 1

days to 7.0 ± 3.4 days compared with the known method, reducing the duration of geltuh-l from 30 ± 0.2 days to 18.2 ± 1.0 days, the frequency of viral superinfections from 8.4 to 3, 3%, HBsAg rapid disappearance

Claims (1)

i fonie contributed according to katam-. through 6 cases of absence of cases of hron - zation process in patients. - Claims of Invention A method of treating acute viral hepatitis B, including the administration of interferon, which has the effect that, in order to keep the treatment timeframe at the expense of increased or antiviral activity in patients with HBsAg hepatitis average weight, introduced Reeferon in dose 1x106 ME twice a day intramuscularly for 7-10 days.